ILB-2109

Phase 2Small molecule

IInnolake Biopharm

ILB-2109 is one of 16 small molecule programs targeting Advanced Solid Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid MalignanciesRecruiting

Advanced Solid MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

24 competitors in Advanced Solid Malignancies

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

6 2

Abraxane

Bristol-Myers Squibb

Phase 2

2 3

Gemzar

Johnson & Johnson

Phase 2

2 4

Erbitux

IImclone

Phase 2

2 5

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 6

Herceptin

Roche

Phase 1

2 7

Yervoy

Bristol-Myers Squibb

Phase 1

1 8

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 9

Liposomal Irinotecan

Astellas

Phase 1

1 10

DATROWAY

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Recruiting·IInnolake Biopharm·Phase 1/2·NCT05955105·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ILB-2109. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ILB-2109 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ILB-2109. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innolake Biopharm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInnolake Biopharm

ILB-2109

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News